Johnson & Johnson and Centocor acquisition talks break down
This article was originally published in Clinica
Johnson & Johnson and US biotechnology company Centocor have reportedly broken off talks concerning an acquisition of the smaller company in a share deal which had been valued at over $3 billion. Sources have, however, indicated that talks may resume at a later date. Both companies declined to comment.